Related Experiment Videos
Advances in paediatric pharmacotherapy
1College of Pharmacy, Ohio State University, Columbus 43210.
Insights
Paediatric pharmacotherapy faces challenges due to a lack of specific drug dosage guidelines for children. Continued advances in paediatric therapeutics offer hope for improved drug efficacy and safety in this population.
Area of Science:
- Pharmacology and Therapeutics
- Paediatric Medicine
- Drug Development
Background:
- Significant differences exist in body composition and organ function between paediatric and adult populations.
- Current drug dosage guidelines are lacking for the majority of medications in neonates, infants, and children.
- There is a substantial need for more research into the pharmacokinetics, pharmacodynamics, efficacy, and safety of drugs in paediatric patients.
Purpose of the Study:
- To review recent developments and ongoing challenges in paediatric pharmacotherapy.
- To highlight key areas of progress and unmet needs in the treatment of childhood diseases.
- To emphasize the importance of evidence-based drug use in paediatric populations.
Main Methods:
- Review of current literature on paediatric drug development and clinical practice.
- Analysis of recent advancements in paediatric therapeutics for various infections and conditions.
- Identification of challenges related to paediatric drug formulations and administration.
Main Results:
- New antibiotics, corticosteroids, and intravenous immunoglobulin have emerged as important treatments for paediatric infections.
- Despite available asthma medications, mortality rates remain a concern.
- Ondansetron shows promise as a safer antiemetic for children undergoing cancer chemotherapy.
- Drug formulation and intravenous delivery methods significantly impact drug concentrations in children.
- Improved vaccination and diarrhoea control could save numerous young lives globally.
Conclusions:
- Paediatric pharmacotherapy is advancing, with new treatments becoming available.
- Addressing the lack of paediatric-specific drug guidelines and formulations is crucial.
- Further research is essential to optimize drug efficacy and safety in children.
Abstract:
Marked differences in body composition and organ function development have been demonstrated among neonates, infants, and children versus adults. Specific dosage guidelines for the paediatric population, however, are still not available for the majority of marketed drugs. Much needs to be learned about the pharmacokinetics, pharmacodynamics, comparative efficacy and safety of drugs in infants and children. Recent developments in paediatric therapeutics include the availability of several new antibiotics for the treatment of infections including, streptococcal pharyngitis, otitis media, bacterial meningitis, herpes encephalitis, neonatal herpes, and AIDS. Corticosteroids and intravenous immunoglobulin have become important adjunctive treatments for certain infections. A variety of drugs are available to treat asthma but the mortality due to this disease is still increasing. The identification of a gene defect in patients with cystic fibrosis could lead to more effective treatment in the future. Ondansetron, marketed for use in adults only, shows promise as a more effective and safer antiemetic in children receiving cancer chemotherapy. Numerous drugs are not available in suitable dosage forms for paediatric use and extemporaneous formulations are required. Documentation on the stability of the reformulated drugs is therefore needed. Studies have shown that the methods used for intravenous delivery can influence the serum concentrations of drugs in infants and children. Large numbers of children could be saved worldwide solely with improved vaccination and control of diarrhoea. Despite this, it is encouraging to witness the continued advances being made in paediatric pharmacotherapy.